“…Due to the widespread and regular use of green tea and its cardiovascular benefits, concurrent use with ticagrelor among ACS patients receiving single or dual antiplatelet therapy is essentially unavoidable, but few studies have been performed. Studies have indicated that TPs or the four catechins exerted moderate to strong inhibitory effects on metabolic enzymes (cytochrome [CYP] P450 superfamily and UDP‐glucuronosyltransferase superfamily), as well as uptake and efflux transporters (Knop et al., 2015; Mohamed & Frye, 2011; Mohamed, Tseng, & Frye, 2010; Muto, Fujita, Yamazaki, & Kamataki, 2001; Nishikawa et al., 2004). Hence, in the case of daily use, whether the long‐term exposure of green tea may affect the absorption, distribution, metabolism, and/or excretion of ticagrelor, and potentially cause pharmacodynamic alteration, particularly for those patients with high risk of cardiovascular events, is yet unknown.…”